ABSTRACT
The aim of our prospective single-center study was to assess the loss of bone mineral density (BMD) in the year following stroke with hemiplegia. We evaluated functional disability and bone mineral density (BMD) in 18 patients immediately following and at 1 year of stroke with hemiplegia. The most significant variation in BMD concerns the femoral neck on the hemiplegic side: -0.0551±0.0548g/cm2: -6.85%. This loss is correlated with the functional motor score (Fugl-Meyer Assessment) (r=0.7573; P=0.0004). During follow-up, 11/18 patients fell and 2/18 had a fracture.
Subject(s)
Bone Density , Stroke , Hemiplegia/etiology , Humans , Prospective Studies , Stroke/complicationsABSTRACT
INTRODUCTION: Prostatic abscesses are usually diagnosed in the setting of bacterial prostatitis. Rarely, they reveal or complicate granulomatous prostatitis. CASE REPORT: A 55-year-old man was admitted for acute urinary retention. Urine culture was sterile, with leukocyturiaâ¯>â¯106/ml. After failure of antibiotic therapy with cefotaxime, CT scan revealed a necrotic prostatic collection and a nodular non-necrotic tissular lesion in the left upper lung lobe. Trans-rectal drainage of the prostatic lesion and lung biopsies revealed granuloma with multinucleated giant cells (without mycobacteria). The diagnosis of granulomatosis with polyangiitis was confirmed by high level of anti-proteinase 3 antibodies. Treatment with steroids and rituximab resulted in apyrexia, regression of the inflammatory syndrome and clinical manifestations. CONCLUSION: The diagnosis of granulomatosis with polyangiitis should be considered in the presence of a non-infectious granulomatous prostatitis with systemic involvement.
Subject(s)
Abscess/complications , Granulomatosis with Polyangiitis/complications , Prostatitis/complications , Abscess/diagnosis , Abscess/drug therapy , Glucocorticoids/therapeutic use , Granulomatosis with Polyangiitis/diagnosis , Granulomatosis with Polyangiitis/drug therapy , Humans , Male , Middle Aged , Prostatitis/diagnosis , Prostatitis/drug therapy , Rituximab/therapeutic use , Urinary Retention/diagnosis , Urinary Retention/drug therapy , Urinary Retention/etiologyABSTRACT
Olfactory dysfunction and altered neurogenesis are observed in several neurodegenerative disorders including Huntington disease (HD). These deficits occur early and correlate with a decline in global cognitive performance, depression and structural abnormalities of the olfactory system including the olfactory epithelium, bulb and cortices. However, the role of olfactory system dysfunction in the pathogenesis of HD remains poorly understood and the mechanisms underlying this dysfunction are unknown. We show that deficits in odour identification, discrimination and memory occur in HD individuals. Assessment of the olfactory system in an HD murine model demonstrates structural abnormalities in the olfactory bulb (OB) and piriform cortex, the primary cortical recipient of OB projections. Furthermore, a decrease in piriform neuronal counts and altered expression levels of neuronal nuclei and tyrosine hydroxylase in the OB are observed in the YAC128 HD model. Similar to the human HD condition, olfactory dysfunction is an early phenotype in the YAC128 mice and concurrent with caspase activation in the murine HD OB. These data provide a link between the structural olfactory brain region atrophy and olfactory dysfunction in HD and suggest that cell proliferation and cell death pathways are compromised and may contribute to the olfactory deficits in HD.
Subject(s)
Huntington Disease/genetics , Neurons/metabolism , Olfactory Bulb/metabolism , Olfactory Mucosa/metabolism , Animals , Atrophy/metabolism , Atrophy/pathology , Brain/metabolism , Brain/pathology , Cell Death/genetics , Cell Proliferation/genetics , Disease Models, Animal , Humans , Huntington Disease/pathology , Mice , Neurogenesis/genetics , Neurons/pathology , Olfactory Bulb/pathology , Olfactory Mucosa/pathology , Signal Transduction/genetics , Smell/geneticsABSTRACT
Tuberculosis is a human disease caused by Mycobacteriumtuberculosis, and transmitted by airborne pathway. Documented cases of tuberculosis infection in healthcare workers have been reported in both developed and developing countries. Early recognition of potentially infectious cases, immediate implementation of airborne precautions and prompt medical treatment of cases, are required to lower the risk of disease transmission. Molecular biology techniques allow earlier diagnosis. In the event of non-compliance with airborne precautions, the investigation will further have to establish exhaustive lists of potentially exposed healthcare workers and patients, looking for cases of latent tuberculosis infections whose treatment should help avoid active tuberculosis disease.
Subject(s)
Cross Infection/prevention & control , Delivery of Health Care/organization & administration , Health Personnel , Infection Control , Occupational Exposure , Tuberculosis , Cross Infection/diagnosis , Cross Infection/epidemiology , Delivery of Health Care/standards , Diagnostic Techniques and Procedures/standards , Health Personnel/organization & administration , Health Personnel/statistics & numerical data , Humans , Infection Control/organization & administration , Infection Control/standards , Mass Screening/methods , Mass Screening/organization & administration , Mass Screening/standards , Occupational Exposure/prevention & control , Occupational Exposure/statistics & numerical data , Risk Reduction Behavior , Tuberculosis/diagnosis , Tuberculosis/epidemiology , Tuberculosis/prevention & control , Tuberculosis/transmissionABSTRACT
BACKGROUND: Mastocytosis is characterized by the accumulation/proliferation of abnormal mast cells. The frequency of isolated cutaneous involvement in adults with mastocytosis has not been fully determined. The main objective of our study was to assess the frequency of isolated cutaneous mastocytosis (CM) in adults with mastocytosis skin lesions. The second objective was to compare the clinical, histological, biological and imaging features in patients with isolated CM and patients with systemic mastocytosis (SM). METHODS: We included all patients with histology-proven mastocytosis skin lesions between January 2009 and December 2017. The mastocytosis diagnosis was made according to the international diagnostic criteria. All data were collected from a dedicated specific case report. RESULTS: Among 160 patients with mastocytosis skin lesions, 25 patients had isolated CM (15.6%), 105 had SM and 30 (18.7%) patients had undetermined mastocytosis. Skin KIT mutation (OR: 51.9, 95% CI: 3.9-678, P = 0.001) and high bone marrow tryptase (OR: 97.4, 95% CI: 10.3-915, P = 0.001) were strong predictors of SM. The prevalence of osteoporosis was higher in the SM population than in the isolated CM population. Moreover, a decrease in bone mineral density over a short period of follow-up (1-2 years) was associated with SM. There were no differences between the two groups regarding the frequency of mast cell activation symptoms, the presentation of skin lesions, the number of mast cells in the dermis and the level of serum tryptase. We propose considering the KIT mutation status and bone marrow tryptase levels to aid the diagnosis of isolated CM in adult mastocytosis patients. CONCLUSION: Only a small minority of adults with mastocytosis skin lesions has isolated cutaneous involvement. In 18.7% of mastocytosis cases, even complete workup does not allow for a precise classification of patients.
Subject(s)
Mastocytosis, Cutaneous/diagnosis , Adult , Aged , Aged, 80 and over , Biomarkers/analysis , Biopsy , Bone Density , Diagnosis, Differential , Female , Humans , Male , Mastocytosis, Cutaneous/epidemiology , Mastocytosis, Cutaneous/genetics , Middle Aged , Mutation , Prevalence , Proto-Oncogene Proteins c-kit/genetics , Tryptases/analysisABSTRACT
Little is known about osteoporosis in mast cell disorders (MCDs) not related to systemic mastocytosis. We described osteoporosis and fractures in MCDs and showed that systemic mastocytosis was the only studied MCDs associated with osteoporotic vertebral fractures. INTRODUCTION: To describe osteoporosis (OP) and fragility fractures in mast cell disorders (MCDs). METHODS: We retrospectively analyzed data concerning all successive patients with systemic mastocytosis (SM), cutaneous mastocytosis (CM), and mast cell activation syndromes (MCAS) diagnosed in our mastocytosis expert center between 2004 and 2015. We collected data concerning demographic profiles, clinical signs of MCD, osteoporosis, fractures, densitometry, and biological assessment of MCD. We compared CM and MCAS patients with SM patients with regard to the characteristics of OP and fragility fractures. RESULTS: We assessed 89 SM patients, 20 CM patients, and 20 MCAS patients. Osteoporosis was less frequent in CM (15.0%) and MCAS (10.0%) than in SM (44.9%). Similarly, fractures were less frequent in non-SM MCDs, respectively 5.0%, 5.0%, and 28.1%. SM patients displayed high prevalence of vertebral fractures (22.5%), mostly multiple. Conversely, in non-SM patients, vertebral fractures appeared to be uncommon (5%) and more frequently associated with risk factors for osteoporosis. CONCLUSIONS: SM is associated with multiple vertebral osteoporotic fractures, whereas CM and MCAS do not appear to be associated with this phenotype.
Subject(s)
Mastocytosis/complications , Osteoporotic Fractures/etiology , Spinal Fractures/etiology , Adult , Bone Density/physiology , Female , France/epidemiology , Hip Joint/physiopathology , Humans , Lumbar Vertebrae/physiopathology , Male , Mastocytosis/epidemiology , Mastocytosis/physiopathology , Mastocytosis, Cutaneous/complications , Mastocytosis, Cutaneous/epidemiology , Mastocytosis, Cutaneous/physiopathology , Mastocytosis, Systemic/complications , Mastocytosis, Systemic/epidemiology , Mastocytosis, Systemic/physiopathology , Middle Aged , Osteoporosis/epidemiology , Osteoporosis/etiology , Osteoporosis/physiopathology , Osteoporotic Fractures/epidemiology , Osteoporotic Fractures/physiopathology , Prevalence , Retrospective Studies , Spinal Fractures/epidemiology , Spinal Fractures/physiopathologyABSTRACT
Olfactory dysfunction is observed in several neurological disorders, including Huntington disease (HD), and correlates with global cognitive performance, depression and degeneration of olfactory regions in the brain. Despite clear evidence demonstrating olfactory dysfunction in HD patients, only limited details are available in murine models and the underlying mechanisms are unknown. In order to determine if alterations in the olfactory bulb (OB) are observed in HD we assessed OB weight or area from 3 to 12â¯months of age in the BACHD transgenic lines (TG5 and TG9). A significant decrease in the OB was observed at 6 and 12â¯months of age compared to WT. We also detected increased mRNA and protein expression of mutant huntingtin (mHTT) in the OB of TG5 compared to TG9 at specific ages. Despite the higher expression of mHTT in the TG5 OBs, there was increased nuclear accumulation of mHTT in the OB of TG9 compared to WT and TG5 rats. As we observed atrophy of the OB in the BACHD rats we assessed for caspase activation, a known mechanism underlying the cell death observed in HD. We characterized caspase-3, -6, -8 andâ¯-â¯9 mRNA and protein expression levels in the OB of the BACHD transgenic lines at 3, 6 and 12â¯months of age. Alterations in caspase mRNA and protein expression were detected in the TG5 and TG9 lines. However, the changes observed in the mRNA and protein levels are in some cases discordant, suggesting that the caspase protein modifications detected may be more attributable to post-translational modifications. The caspase activation studies support that cell death may be increased in the rodent HD OB and further our understanding of the olfactory dysfunction and the role of caspases in the pathogenesis of HD.
Subject(s)
Caspases/metabolism , Huntington Disease/complications , Olfaction Disorders/etiology , Olfactory Bulb/enzymology , Olfactory Bulb/pathology , Animals , Atrophy/etiology , Atrophy/pathology , Disease Models, Animal , Enzyme Activation/physiology , Humans , Huntingtin Protein/genetics , Huntington Disease/enzymology , Huntington Disease/pathology , Olfaction Disorders/enzymology , Olfaction Disorders/pathology , Rats , Rats, TransgenicABSTRACT
Flea identification is a significant issue because some species are considered as important vectors of several human pathogens that have emerged or re-emerged recently, such as Bartonella henselae (Rhizobiales: Bartonellaceae) and Rickettsia felis (Rickettsiales: Rickettsiaceae). Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) has been evaluated in recent years for the identification of multicellular organisms, including arthropods. A preliminary study corroborated the usefulness of this technique for the rapid identification of fleas, creating a preliminary database containing the spectra of five species of flea. However, longterm flea preservation in ethanol did not appear to be an adequate method of storage in the context of specimen identification by MALDI-TOF MS profiling. The goal of the present work was to assess the performance of MALDI-TOF MS in the identification of seven flea species [Ctenocephalides felis (Siphonaptera: Pulicidae), Ctenocephalides canis, Pulex irritans (Siphonaptera: Pulicidae), Archaeopsylla erinacei (Siphonaptera: Pulicidae), Leptopsylla taschenbergi (Siphonaptera: Ceratophyllidae), Stenoponia tripectinata (Siphonaptera: Stenoponiidae) and Nosopsyllus fasciatus (Siphonaptera: Ceratophyllidae)] collected in the field and stored in ethanol for different periods of time. The results confirmed that MALDI-TOF MS can be used for the identification of wild fleas stored in ethanol. Furthermore, this technique was able to discriminate not only different flea genera, but also the two congeneric species C. felis and C. canis.
Subject(s)
Dog Diseases/classification , Flea Infestations/veterinary , Hedgehogs , Insect Vectors/classification , Siphonaptera/classification , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/veterinary , Algeria , Animals , Dogs , Ethanol , Flea Infestations/classification , Spain , Specimen Handling/veterinary , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methodsABSTRACT
OBJECTIVES: Veillonella parvula is an anaerobic Gram-negative coccus rarely involved in bone and joint infections. PATIENTS AND METHOD: We report the case of a Veillonella parvula vertebral osteomyelitis (VO) in a female patient without any risk factor. RESULTS: The 35-year-old patient was immunocompetent and presented with Veillonella parvula VO. She was admitted to hospital for inflammatory lower back pain. The discovertebral sample was positive for Veillonella parvula. Literature data on Veillonella VO is scarce. Reported cases usually occurred in immunocompromised patients. Diagnosis delay can be up to four months. Patients are usually afebrile. Outcome with antimicrobial treatment alone is favorable in half of cases. Other patients must undergo surgery. CONCLUSIONS: Veillonella VO may occur in immunocompetent patients and have a clinical spectrum of mechanical lower back pain.
Subject(s)
Discitis/diagnosis , Gram-Negative Bacterial Infections/diagnosis , Lumbar Vertebrae/microbiology , Veillonella , Adult , Discitis/microbiology , Female , Gram-Negative Bacterial Infections/microbiology , Humans , Immunocompetence , Osteomyelitis/diagnosis , Osteomyelitis/microbiology , Veillonella/isolation & purification , Veillonella/physiologyABSTRACT
The transmission of an infectious disease can occur through exposure to blood or other potentially infectious body fluids, particularly in the event of skin-puncture injuries for healthcare workers, and during sexual intercourse. These situations are known as accidental blood exposures and sexual exposures respectively. Combined actions carried out have allowed to significantly reduce risks, either to healthcare professionals (by standard precautions, provision of safety devices, Hepatitis B vaccination made compulsory in the 1990s, antiretroviral post-exposure prophylaxis that should be initiated as soon as possible after exposure), or to people engaging in unprotected sex (by prevention messages, condom promotion, and antiretroviral post-exposure prophylaxis). In any case, treatment of people infected by chronic diseases such as HBV or HIV, as well as possible drug eradication of HCV, are key for decreasing post-exposure risk of disease transmission. Post-exposure prophylaxis should be initiated as early as possible and intended for use only in patients with high-risk exposures. Knowledge of source person serostatus, information of exposed person on prevention, benefits and risks of treatment, and follow-up procedure are key points. Procedures to be followed in the event of an exposure must be known by all. Arrangements set up to allow risk assessment and management of exposed people rely on hospital services operating on a permanent basis.
Subject(s)
Infection Control , Infectious Disease Transmission, Patient-to-Professional , Occupational Exposure , Sexually Transmitted Diseases, Viral , Virus Diseases , HIV Infections/blood , HIV Infections/prevention & control , HIV Infections/transmission , Health Personnel/statistics & numerical data , Hepatitis B/blood , Hepatitis B/prevention & control , Hepatitis B/transmission , Hepatitis C/blood , Hepatitis C/prevention & control , Hepatitis C/transmission , Humans , Infection Control/methods , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Infectious Disease Transmission, Patient-to-Professional/statistics & numerical data , Occupational Exposure/prevention & control , Occupational Exposure/statistics & numerical data , Post-Exposure Prophylaxis/methods , Risk Factors , Sexually Transmitted Diseases, Viral/epidemiology , Sexually Transmitted Diseases, Viral/transmission , Virus Diseases/epidemiology , Virus Diseases/prevention & control , Virus Diseases/transmissionABSTRACT
Arthropod vectors can transmit pathogenic microorganisms from one vertebrate to another during their blood meal. Although some vector-borne diseases have been eradicated in the Mediterranean area, such as malaria and dengue, recent endemic microorganisms (Toscana virus, Rickettsia spp.) remain neglected even though they cause many more cases. New diagnostic tools and innovative tools for the identification and characterization of vector species and microorganisms have been developed at IHU Méditerranée Infection, either internally or through collaborative and integrated projects. We have detected Rickettsia slovaca as a human pathogen and have described the disease; we have shown that Rickettsia felis can be transmitted by Anopheles mosquitoes; we have emphasized the increasing importance of bedbug (Cimex lectularius) as a potential vector of Bartonella quintana; and we have described the Toscana virus, a major agent of meningitis and meningoencephalitis which was disseminated in North Africa and Central and Eastern Europe, where it frequently cocirculates with a large number of newly described phleboviruses transmitted by sand flies.
ABSTRACT
The objective of our prospective study is to specify the variability of densitometric response to Denosumab, given in the second line, and to try to understand the reasons. All menopausal patients with primary osteoporosis, treated by Denosumab in our centre from 2014 to 2015, were included in this open prospective work. At T0, the patient's age, type of fracture, and previous treatments were collated. At T0 and T1, after 1 year of treatment by Dmab, a DXA of the spine and the hip and a determination of CTX were performed. Sixty-three patients aged 68.8 ± 8.3 years were included. The median number of treatments prescribed for osteoporosis before switch to Denosumab was 2.4. The median duration of these treatments was 7.2 years. At T1, CTX was less than 33 pg/ml (minimum threshold for our assay kit) in all patients. The median BMD in the spine increased by + 5.44% compared to T0. 14 patients in the upper quartile had a median BMD gain in the spine of + 11.07%. Fourteen patients in the lower quartile had a median BMD gain in the spine of + 0.6%. Only the duration of previous treatments, which was greater in the non-responder group, differed between these two groups. In the total cohort, the spinal densitometric gain was negatively correlated with the age of the patient at baseline (p = 0.04), the duration of previous treatment (p = 0.02), and positively with the CTX level (p = 0.05). The Dmab densitometric response is highly variable, partly explained by the duration of previous treatments and the level of bone resorption at initiation of treatment.
Subject(s)
Bone Density Conservation Agents/therapeutic use , Bone Remodeling/drug effects , Denosumab/therapeutic use , Osteoporosis, Postmenopausal/drug therapy , Pelvic Bones/drug effects , Spine/drug effects , Absorptiometry, Photon , Aged , Aged, 80 and over , Bone Density Conservation Agents/adverse effects , Denosumab/adverse effects , Densitometry , Female , France , Humans , Middle Aged , Osteoporosis, Postmenopausal/diagnostic imaging , Osteoporosis, Postmenopausal/physiopathology , Pelvic Bones/diagnostic imaging , Pelvic Bones/physiopathology , Prospective Studies , Spine/diagnostic imaging , Spine/physiopathology , Time Factors , Treatment OutcomeABSTRACT
INTRODUCTION: Pristinamycin is an antibiotic of the streptogramin family; few adverse effects of this drug are reported, only cutaneous and digestive ones. Arthralgia and myalgia may however be observed although not mentioned in the summary of product characteristics. OBJECTIVE: Description and analysis of cases of pristinamycin-induced arthralgia and/or myalgia registered in the French database of pharmacovigilance. METHOD: We carried out a targeted search of the database, selecting case patients presenting with arthralgia and muscle pain and excluding those associated with sensitivities or allergies to pristinamycin. RESULTS: We retrieved 15 case patients of pristinamycin-induced arthralgia and myalgia. Pristinamycin was the only potentially incriminated drug for seven case patients. CONCLUSION: Although not serious, this adverse effect deserves to be better known by physicians to optimize therapeutic management.
Subject(s)
Anti-Bacterial Agents/adverse effects , Arthralgia/chemically induced , Myalgia/chemically induced , Pristinamycin/adverse effects , Adult , Aged , Aged, 80 and over , Databases, Factual , Female , France , Humans , Male , Middle Aged , Pharmacovigilance , Retrospective Studies , Young AdultABSTRACT
We have developed a Watt-level single-frequency tunable fiber laser in the 915-937 nm spectral window. The laser is based on a neodymium-doped fiber master oscillator power amplifier architecture, with two amplification stages using a 20 mW extended cavity diode laser as seed. The system output power is higher than 2 W from 921 to 933 nm, with a stability better than 1.4% and a low relative intensity noise.
ABSTRACT
INTRODUCTION: Lymphogranuloma venereum (LG) is a sexually transmitted infection (STI) caused by Chlamydia trachomatis L serovar. METHODS: These five consecutive cases aim to highlight the risk of LG misdiagnosis, in case of initial presentation with isolated inguinal adenitis. RESULTS: Five men (mean age: 30±7 years) were seen in an internal medicine department, for inguinal adenopathy. One patient had clinical signs of urethritis. None presented an associated rectitis. Three patients had a history of STI, and two had a discovery of related HIV disease. Urinary polymerase chain reaction (PCR) was positive for the symptomatic patient and negative for the others. Lymph node PCR was positive in all patients within a L2b serotype (searched in 4 out of 5 cases). CONCLUSION: LG should be evoked in any patient with inguinal adenomegaly, particularly in case of STI history or risk factors. Negativity of urinary PCR should lead to further investigations, essentially a lymph node cytopuncture to evidence C. trachomatis.
Subject(s)
Lymphadenopathy/diagnosis , Lymphogranuloma Venereum/diagnosis , Adult , Chlamydia trachomatis/genetics , Chlamydia trachomatis/isolation & purification , Diagnosis, Differential , Humans , Lymphadenopathy/microbiology , Lymphogranuloma Venereum/microbiology , Male , Polymerase Chain Reaction , Young AdultABSTRACT
A retrospective, multicentre study involving 52 patients was carried out to define the causes and characteristics of pregnancy-related osteoporosis. The mean number of vertebral fractures occurring during the last trimester of pregnancy or at the time of delivery was 3.8. This is often promoted by risk factors before or during pregnancy. INTRODUCTION: In order to define the causes or predisposing factors of pregnancy-related osteoporosis and its clinical, radiological and bone density characteristics, laboratory findings, course and outcome, we carried out a retrospective multicentre study. METHODS: The records of 52 women hospitalised over the last 10 years in the rheumatology departments of six French university hospitals and with a diagnosis of pregnancy-related osteoporosis were examined. RESULTS: The patients' mean age at time of fracture was 32.1 years. In 10 patients, the fractures had occurred during the last trimester of pregnancy, and in 36 at the time of delivery or during the first 2 months post-partum. The mean number of vertebral fractures was 3.8 ± 2.0. Thirty three of the 52 patients had a risk factor of low bone mass before pregnancy. Twelve had disorders or treatments (heparin) that might promote osteoporosis during pregnancy, while 14 had no trigger factors before or during pregnancy. Overall, phosphate and calcium levels were normal, except for hyperphosphoraemia in lactating women (90%). On DXA scan, osteoporosis predominated in the trabecular bone (spinal T-score - 3.4, hip T-score - 2). Only 10 patients had a repeat fracture, and the increase in bone mineral density during follow-up was considerable, and improved by bisphosphonates (annual gain + 10% in the spine) or teriparatide (+ 15%). CONCLUSIONS: Pregnancy-related osteoporosis gives rise to multiple vertebral fractures. It is often promoted by risk factors before or during pregnancy. Its mechanism is still unknown. Treatment with bisphosphonates or teriparatide appears to improve the recovery of bone mineral density.
Subject(s)
Osteoporosis/etiology , Pregnancy Complications/physiopathology , Absorptiometry, Photon/methods , Adult , Bone Density/physiology , Bone Density Conservation Agents/therapeutic use , Female , Humans , Middle Aged , Osteoporosis/drug therapy , Osteoporosis/physiopathology , Pregnancy , Pregnancy Complications/drug therapy , Retrospective Studies , Risk Factors , Spinal Fractures/drug therapy , Spinal Fractures/etiology , Spinal Fractures/physiopathology , Young AdultABSTRACT
BACKGROUND: Mastocytosis is difficult to diagnose, especially when systemic mast cell activation symptoms are not present or involve only one extracutaneous organ. OBJECTIVE: The main objective was to evaluate the accuracy of the bone marrow tryptase level in the diagnosis of systemic mastocytosis in patients with a clinical suspicion of mastocytosis. METHODS: We included all adult patients evaluated in our centre between December 2009 and 2013 for suspected mastocytosis as part of a standardized procedure and who had a bone marrow and serum tryptase assay on the same day. The diagnosis of systemic mastocytosis was established on the basis of the World Health Organization criteria as the gold standard. The accuracy of the bone marrow tryptase level in the diagnosis of systemic mastocytosis was assessed by a receiver operating characteristics curve analysis. The different sensitivity and specificity values, corresponding to the set of possible bone marrow tryptase level cut-off values, were estimated with 95% confidence intervals. RESULTS: Seventy-three patients were included. The diagnosis of systemic mastocytosis was established in 43 patients (58.9%). The median bone marrow tryptase level was 423 µg/L [95% CI: 217-868] in the systemic mastocytosis group and 7.5 µg/L [95% CI: 4.6-17.1] in the non-systemic mastocytosis group (P < 0.001). A cut-off value of 50 µg/L for bone marrow tryptase identified systemic mastocytosis with a sensitivity of 93.0% [95% CI: 80.9-98.5%] and a specificity of 90.0% [95% CI: 73.5-97.9%]. CONCLUSION AND CLINICAL RELEVANCE: The bone marrow tryptase level appears to be a valuable diagnostic criterion for confirming systemic mastocytosis. If this diagnosis can reliably be excluded by evaluation of the bone marrow tryptase level, there would be no need to perform a bone marrow biopsy.
Subject(s)
Bone Marrow/enzymology , Bone Marrow/pathology , Mastocytosis, Systemic/diagnosis , Mastocytosis, Systemic/enzymology , Tryptases/metabolism , Adolescent , Adult , Aged , Biomarkers , Biopsy , Female , Humans , Male , Middle Aged , ROC Curve , Reproducibility of Results , Tryptases/blood , Young AdultABSTRACT
Efficient operation of an Nd-doped fiber laser operating in a wavelength-tunable configuration using a volume Bragg grating (VBG) is reported in this Letter. A high-power operation on the 4F3/2-4I9/2 transition of Nd3+ at short wavelengths below 900 nm is demonstrated for the first time in silica fibers. A high-efficiency (47% laser conversion) output power up to 22 W and a narrow linewidth of 0.035 nm are achieved. This configuration is compared with a more conventional fiber laser setup using a bandpass filter and a highly reflective dichroic mirror.